Expression of topoisomerase II alpha, Ki-67 and p53 in early stage laryngeal carcinomas not featuring vocal cord fixation

APMIS

Volumn 108, Issue 10, 2000, Pages 689-696

  Horibe, Yoshimune ^a   Murakami, Masamoto ^a,b   Komori, Katsuhiko ^b   Imaeda, Yoshihiro ^a,b   Kasahara, Masao ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Immunohistochemistry; Ki 67; Larynx; p53; Squamous cell carcinoma; Topoisomerase II alpha

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); ISOENZYME; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION; VOCAL CORD;

EID: 0034525162     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0463.2000.d01-16.x     Document Type: Article

References (41)

1. Larynx
2. The clinical assessment of proliferation and growth in human tumours: Evaluation of methods and applications as prognostic variables
3. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication
4. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry
5. Advances in flow cytometry for diagnostic pathology
6. A rapid method to determine proliferation patterns of normal and malignant tissues by H3 mRNA in situ hybridization
7. In situ localization of S-phase-specific histone (H3) mRNA in Bowen's disease
8. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation
9. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form
10. Cytosolic Ca2+ transients are not required for platelet-derived growth factor to induce cell cycle progression of vascular smooth muscle cells in primary culture. Actions of tyrosine kinase
11. Little missed markers and Ki-67
12. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe
13. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells
14. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle
15. Immunohistochemical study of DNA topoisomerase II in human gastric disorders
16. Immunohistochemical and two-parameter flow cytometric study of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor
17. Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells
18. The p53 tumour suppressor gene
19. p53, the cellular gatekeeper for growth and division
20. A p53-dependent mouse spindle checkpoint
21. Identification of a p53-dependent negative response element in the bcl-2 gene
22. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas
23. Apoptosis-regulated factors p53, Bcl-2, and Bax in neuroendocrine lung tumors
24. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some neoplasms
25. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme
26. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
27. The cell proliferation-associated antigen of antibody Ki-67: A very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining protein
28. Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma
29. DNA topoisomerase poisons as antitumor drugs
30. DNA topoisomerases as anticancer drug targets
31. Expression of MDR1, GST-pi and topoisomerase II as an indicator of clinical response to adriamycin
32. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle
33. Implications of the p53 tumor-suppressor gene in clinical oncology
34. p53: Oncogene or antioncogene?
35. Aberrant p53 expression in astrocytic neoplasms of the brain: Association with proliferation
36. Prognostic significance of Ki67 (MIB1) proliferation index and p53 overexpression in chondrosarcomas
37. p53 expression and cell proliferation in squamous cell carcinomas of the head and neck
38. Expression of p53 protein in advanced head and neck squamous cell carcinoma before and after chemotherapy
39. Prognostic significance of clinical factors and p53 expression in patients with glottic carcinoma treated with radiation therapy